Semma Therapeutics is a cell therapy company founded by Doug Melton of Harvard University and financed by ARCH Venture, MPM, and F-Prime. The company was subsequently acquired by Vertex for approximately $1B in late 2019.
In May 2019, Occam placed Mary Kay Fenton as CFO, having years of experience working with fast-growing biotech companies, most recently as EVP and CFO of Achillion Pharmaceuticals. With Fenton in place, Semma was subsequently acquired by Vertex for $1B.
About Occam Global
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.